Long-term Prognosis of Patients With Hepatitis B Related Acute-on-chronic Liver Failure
The Investigation on Long-term Outcomes and Prognostic Factors of Patients With Hepatitis B Related Acute-on-chronic Liver Failure
1 other identifier
observational
300
1 country
1
Brief Summary
This study is to investigate the long-term outcomes and prognostic risk factors in patients recovered from hepatitis B virus related acute on-chronic liver failure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 13, 2020
CompletedFirst Posted
Study publicly available on registry
March 17, 2020
CompletedStudy Start
First participant enrolled
May 15, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedNovember 29, 2024
November 1, 2024
4.6 years
March 13, 2020
November 26, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
adverse events
Adverse events included decompensated cirrhosis, hepatocellular carcinoma, liver transplantation, and death.
5 years
Study Arms (1)
HBV-ACLF
To investigate the clinical events and prognosis of patients with hepatitis b associated acute on-chronic liver failure
Eligibility Criteria
This study population were patients with hepatitis b-related acute on-chronic liver failure in the department of infectious diseases, the third affiliated hospital of sun yat-sen university.
You may qualify if:
- Age from 18 to 65 years old;
- The diagnosis consistent with hepatitis b associated chronic acute liver failure；
- After hospitalization, the survival time \> 90 days；
- The inpatient clinical data are complete.
You may not qualify if:
- Human immunodeficiency virus infection or congenital immune deficiency diseases;
- Liver cancer and other tumors, autoimmune liver disease, genetic and metabolic liver disease, or other serious diseases that significantly affect patient survival;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510630, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Liang Peng, Doctor
Third Affiliated Hospital, Sun Yat-Sen University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professer
Study Record Dates
First Submitted
March 13, 2020
First Posted
March 17, 2020
Study Start
May 15, 2020
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
November 29, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- The data will be shared beginning 3 months and ending 5 years following the article publication.
- Access Criteria
- Proposals should be directed to xxx@yyy. To gain access, data requestors need to sign a data access agreement.
Individual participant data that underline the results reported in this article (text, tables, figures and appendices) will be shared.